{"protocolSection":{"identificationModule":{"nctId":"NCT04627870","orgStudyIdInfo":{"id":"ACOART intracranial ISR pilot"},"organization":{"fullName":"Acotec Scientific Co., Ltd","class":"INDUSTRY"},"briefTitle":"ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis","officialTitle":"A Prospective, Multi-center, Randomized Controlled Trial to Evaluate the Safety and Feasibility of Intracranial Drug-coated Balloon Catheter in the Treatment of Intracranial In-stent Restenosis"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-05-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-04","studyFirstSubmitQcDate":"2020-11-10","studyFirstPostDateStruct":{"date":"2020-11-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-03","lastUpdatePostDateStruct":{"date":"2023-08-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Acotec Scientific Co., Ltd","class":"INDUSTRY"},"collaborators":[{"name":"Beijing Tiantan Hospital","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate the safety and feasibility of drug coated balloon in treatment of intracranial in-stent restenosis.","detailedDescription":"This study is a prospective, multi-center, randomized controlled trial using drug coated balloon versus uncoated PTA balloon in treatment of intracranial in-stent restenosis."},"conditionsModule":{"conditions":["Intracranial Atherosclerosis","Stroke"],"keywords":["Intracranial Atherosclerosis","In-stent restenosis","drug coated balloon"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":20,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"DCB group","type":"EXPERIMENTAL","description":"use drug (paclitaxel) coated balloon to treat intracranial in-stent restenosis","interventionNames":["Device: drug (paclitaxel) coated balloon"]},{"label":"PTA group","type":"ACTIVE_COMPARATOR","description":"use PTA balloon to treat intracranial in-stent restenosis","interventionNames":["Device: PTA balloon"]}],"interventions":[{"type":"DEVICE","name":"drug (paclitaxel) coated balloon","description":"use drug (paclitaxel) coated balloon catheter to treat intracranial in-stent restenosis","armGroupLabels":["DCB group"]},{"type":"DEVICE","name":"PTA balloon","description":"use traditional PTA balloon with NMPA approval of indication for treating intracranial stenosis","armGroupLabels":["PTA group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Target vessel stroke or death event","description":"Target-vessel related stroke (bleeding and ischemia) or death within 30 days postoperatively.","timeFrame":"within 30 days post-procedure"}],"secondaryOutcomes":[{"measure":"device success rate","description":"The balloon dilatation catheter was able to reach the treated lesion, successfully dilated without rupture, and successfully retreated.","timeFrame":"assessed during procedure"},{"measure":"target vessel ischemia stroke event","description":"The incidence of recurrent ischemic stroke in the target vessel supply area 31 days to 12 months after surgery","timeFrame":"between 31days and 12months post-procedure"},{"measure":"Cerebral parenchyma hemorrhage, subarachnoid hemorrhage or intraventricular hemorrhage events","description":"Any cerebral parenchyma hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage confirmed by MRI or CT from 31 days to 12 months post procedure","timeFrame":"between 31 days and 12 months post-procedure"},{"measure":"target vessel death event","description":"Target-vessel related death 31 days to 12 months postoperatively","timeFrame":"between 31 days and 12 months post-procedure"},{"measure":"National Institutes of Health Stroke Scale score","description":"National Institutes of Health Stroke Scale score at 12 months postoperatively(0-42, higher scores mean a worse outcome)","timeFrame":"at 12 months post-procedure"},{"measure":"Modified Rankin Score score","description":"Modified Rankin Score at 12 months postoperatively(0-5, higher scores mean a worse outcome)","timeFrame":"at 12 months post-procedure"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 to 80 years of age\n* Confirmed by DSA: in-stent restenosis (ISR) at intracranial segment of internal carotid artery, middle cerebral artery, basilar artery and vertebral artery; ISR is defined as \\>50% stenosis within or immediately adjacent (within 5 mm) of the implanted stent and \\>20% absolute luminal loss\n* presence of ISR associated ischemic stroke or transient ischemic attacks even with medical treatment and strict control of risk factor\n* asymptomatic ISR with severe hypoperfusion in the ISR territories, confirmed by a cerebral blood flow decrease of ≥30% when compared with the perfusion on the contralateral side for anterior circulation lesions or the anterior circulation territory for posterior circulation lesions on CT perfusion, and/or by an American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) Collateral Flow Grading System score \\<3 on DSA.\n* the diameter of target vessel is 2.0-4.5mm\n* there is only one intracranial ISR lesion per subject\n* baseline mRS score ≤2\n* Voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with stroke within 2 weeks before procedure;\n* any history of brain parenchyma or other intracranial subarachnoid, subdural or extradural hemorrhage in the past 30 days.\n* Those who have received thrombolysis within 24 hours before procedure;\n* Deterioration of neurological function within 24 hours before procedure (defined as NIHSS score increased by ≥ 4 points over the baseline)\n* patients with thrombus in target vessels.\n* in addition to ISR lesions, there are other primary intracranial lesions that need endovascular treatment.\n* Major surgery (including open femoral, aortic or carotid artery surgery) is planned within the past 30 days or within 90 days.\n* patients with renal artery, iliac artery and cardiac coronary artery requiring simultaneous intervention.\n* Combined with intracranial tumors, aneurysms or intracranial arteriovenous malformations.\n* Cardiac stroke or potential cardiogenic thromboembolism, with any of the following cardiogenic embolism causes: chronic or paroxysmal atrial fibrillation, mitral valve stenosis, mechanical valves, endocarditis, intracardiac thrombus or implant, dilated cardiomyopathy, spontaneous acoustic imaging of the left atrium;\n* patients with myocardial infarction within 6 weeks before procedure.\n* those who cannot tolerate general anesthesia due to insufficiency of heart, lung and other important organs.\n* patients with known severe hepatic and renal dysfunction.\n* patients with hemoglobin \\< 100g / L, platelet count \\< 100,000 / mm3, INR \\> 1.5or with uncorrectable factors leading to bleeding.\n* patients who cannot receive dual antiplatelet therapy due to existing diseases or who are tested to be tolerant to dual antiplatelet therapy.\n* Patients with known severe allergies or contraindications to heparin, paclitaxel, contrast agents and other related intravascular treatment drugs\n* current alcohol or drug abuse, uncontrolled severe hypertension (systolic blood pressure \\> 180mmHg or diastolic blood pressure \\> 110mmHg).\n* Life expectancy \\< 1 year.\n* pregnant or lactating women.\n* patients who are unable to complete follow-up due to cognitive, emotional disorders or mental illness.\n* Patients who are participating in other drug/device clinical trials and have not completed all follow-ups required by the programme;\n* According to the judgement of the investigator, other situations that are not suitable for enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Ning Ma, MD","role":"CONTACT","phone":"010-59978585","email":"maning_03@hotmail.com"}],"overallOfficials":[{"name":"Ning Ma, MD","affiliation":"Beijing Tiantan Hospital","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Beijing Tiantan Hospital","status":"RECRUITING","city":"Beijing","country":"China","contacts":[{"name":"Ning Ma, MD","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002537","term":"Intracranial Arteriosclerosis"},{"id":"D000050197","term":"Atherosclerosis"}],"ancestors":[{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000020765","term":"Intracranial Arterial Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M5476","name":"Intracranial Arteriosclerosis","asFound":"Intracranial Atherosclerosis","relevance":"HIGH"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M22211","name":"Intracranial Arterial Diseases","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000017239","term":"Paclitaxel"}],"ancestors":[{"id":"D000000972","term":"Antineoplastic Agents, Phytogenic"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M19227","name":"Paclitaxel","asFound":"In Patients","relevance":"HIGH"},{"id":"M231","name":"Albumin-Bound Paclitaxel","relevance":"LOW"},{"id":"M25887","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M25886","name":"Antimitotic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}